[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kailera\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":124},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,79,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100654129","phase-1-a-study-to-evaluate-the-impact-of-renal-impairment-on-the-pharmacokinetics-pk-of-ribupatide-100654129",false,"NCT07793929","A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide","A Phase 1, Open Label, Parallel Group Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics of Ribupatide in Healthy Participants and in Participants Living With Severe Renal Impairment or End Stage Kidney Disease","Inclusion Criteria:\n\n* Have body mass index ≥18.5 at Screening.\n* Female Participants: Must not be breastfeeding or planning to breastfeed during the study and for at least 35 days after the study drug dose.\n* Female participants: Must have a negative serum pregnancy test at Screening.\n* Have suitable venous access for blood sampling.\n\nExclusion Criteria:\n\n* Have history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, psychiatric, or neurological disease\u002Fdisorder, including any acute illness, within the past 3 months determined by the Investigator (or delegate) to be clinically relevant.\n* Have abnormal thyroid-stimulating hormone at Screening.\n* Have any history of malignant disease including in situ cervical or prostate cancer within the last 5 years.\n* Have history of or positive test results at the Screening Visit for human immunodeficiency virus (HIV), hepatitis B surface antigen, or hepatitis C virus (HCV) antibody with HCV ribonucleic acid (RNA) confirmation if positive.\n* Have participated in another clinical study of a study drug or investigational device within 30 days or 5 half-lives of the study drug (whichever is longer) prior to Screening.\n* Have received treatment with semaglutide, tirzepatide, glucagon-like peptide-1 receptor (GLP-1R) agonist, GLP-1R\u002Fglucose-dependent insulinotropic polypeptide receptor (GIPR) agonist, or glucagon receptor agonist within 3 months prior to Screening.\n* Have known hypersensitivity to the study drug, glucagon-like peptide-1 (GLP-1) therapies, or any of the study drug ingredients.\n* Have had any vaccinations within 30 days prior to Screening.\n* Have current infection that requires systemically absorbed antibiotic, antifungal, antiparasitic, or antiviral medication within 10 days prior to the dose of study drug.",true,"ALL","18 Years","85 Years",{"count":21,"type":22},32,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection compared with participants with normal renal function.",[28,29,30,31],"End Stage Renal Disease","Renal Impairment","Obesity","Overweight",[31,30,33,34,35,36,37,38],"Ribupatide","KAI-9531","Glucagon-like Peptide-1","GLP-1","Glucose-dependent Insulinotropic Peptide","GIP","NOT_YET_RECRUITING","2026-09-02",{"date":42,"type":43},"2026-09-03","ACTUAL",{"date":45,"type":22},"2026-09-08",{"date":47,"type":22},"2028-02-08",{"name":49,"class":50},"Kailera","INDUSTRY",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100614846","phase-3-efficacy-and-safety-of-ribupatide-administered-once-weekly-in-participants-living-with-obesity-or-overweight-and-diabetes-100614846","NCT07284901","Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes","KaiNETIC-2","Key Inclusion Criteria:\n\n* Diagnosis of type 2 diabetes mellitus (T2DM).\n* Receiving stable therapy for T2DM for 3 months prior to Screening. This includes diet and\u002For exercise alone or in combination with any oral medication for T2DM treatment except for DPP-4 inhibitors. Participants can be treatment naïve if they have an HbA1c of 6.5% to 7.5%, inclusive.\n* BMI ≥27 kg\u002Fm\\^2.\n* History of being unresponsive to at least 1 self-reported effort to lose weight with diet and\u002For exercise in the last 6 months.\n\nKey Exclusion Criteria:\n\n* Current diagnosis or history of type 1 diabetes mellitus (T1DM) or any other type of diabetes except T2DM.\n* History of diabetic ketoacidosis or hyperosmolar state\u002Fcoma within 1 year prior to Screening.\n* History of severe hypoglycemia or hypoglycemia unawareness within 1 year prior to Screening.\n* Started medications within 3 months prior to Screening that may cause significant weight change, including, but not limited to, tricyclic antidepressants, atypical antipsychotics, mood stabilizers, or phentermine.\n* Unstable weight defined as self-reported change in body weight exceeding 5% within 3 months prior to Screening.\n* Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer.\n* Uncontrolled hypertension or unstable cardiovascular disease.\n* History of chronic or acute pancreatitis.\n* Known clinically significant gastric emptying abnormality or chronic treatment with medications that directly affect gastrointestinal (GI) motility if taken for \\>30 days continually within 3 months prior to Screening.\n* History of suicide attempt.\n* History of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder within 2 years prior to Screening.\n* Received treatment with semaglutide, tirzepatide, GLP-1 receptor agonists, GLP-1\u002Fglucose-dependent insulinotropic polypeptide (GIP) agonists, glucagon receptor agonists, or other weight loss medications or treatments aside from diet and exercise within 3 months prior to Screening.\n\nNote: Additional inclusion\u002Fexclusion criteria may apply, per protocol.",{"count":61,"type":22},1156,[63],"PHASE3","The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on:\n\n* Percent change in body weight\n* Change in hemoglobin A1c (HbA1c)",[66,67],"Obesity With Diabetes","Overweight With Diabetes",[30,31,33,34,69,36,70,37,38],"Glucagon-like peptide-1","Diabetes","RECRUITING",{"date":42,"type":43},{"date":74,"type":43},"2026-01-12",{"date":76,"type":22},"2028-04-24",{"name":49,"class":50},167,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100614844","phase-3-efficacy-and-safety-of-ribupatide-in-participants-living-with-obesity-or-overweight-with-weight-related-comorbidities-who-do-not-have-diabetes-100614844","NCT07284875","Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes","KaiNETIC-1","Inclusion Criteria:\n\n* BMI ≥30 kg\u002Fm\\^2 or BMI ≥27 kg\u002Fm\\^2 and previously diagnosed with at least 1 of the following:\n\n  1. hypertension,\n  2. dyslipidemia,\n  3. obstructive sleep apnea, or\n  4. cardiovascular (CV) disease.\n* History of being unresponsive to at least 1 self-reported effort to lose weight with diet and\u002For exercise in the last 6 months.\n\nExclusion Criteria:\n\n* Current diagnosis or history of diabetes mellitus.\n* Started medications within 3 months prior to Screening that may cause significant weight change, including, but not limited to: tricyclic antidepressants, atypical antipsychotics, mood stabilizers, or phentermine.\n* Unstable weight defined as self-reported change in body weight exceeding 5% within 3 months prior to Screening.\n* Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer.\n* Uncontrolled hypertension or unstable cardiovascular disease.\n* History of chronic or acute pancreatitis.\n* Known clinically significant gastric-emptying abnormality or chronic treatment with medications that directly affect gastrointestinal motility.\n* History of suicide attempt.\n* History of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder.\n* Received treatment with semaglutide, tirzepatide, GLP-1 receptor agonist, GLP-1\u002Fglucose-dependent insulinotropic polypeptide (GIP), or glucagon receptor agonist within 3 months prior to Screening.\n\nNote: Additional inclusion\u002Fexclusion criteria may apply, per protocol.",{"count":88,"type":22},2340,[63],"The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.",[30,31],[31,30,33,34,35,36,37,38],{"date":42,"type":43},{"date":95,"type":43},"2025-12-18",{"date":97,"type":22},"2028-03",{"name":49,"class":50},104,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},"100614852","phase-3-efficacy-and-safety-of-ribupatide-administered-once-weekly-compared-with-semaglutide-and-placebo-in-participants-living-with-obesity-who-do-not-have-diabetes-100614852","NCT07284979","Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes","A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes","KaiNETIC-3","Key Inclusion Criteria:\n\n* BMI ≥35 kilograms per square meter (kg\u002Fm\\^2).\n* History of being unresponsive to at least 1 self-reported effort to lose weight with diet and\u002For exercise in the last 6 months.\n\nKey Exclusion Criteria:\n\n* Current diagnosis or history of diabetes mellitus.\n* Started medications within 3 months prior to Screening that may cause significant weight change, including, but not limited to, tricyclic antidepressants, atypical antipsychotics, mood stabilizers, and phentermine.\n* Unstable weight defined as self-reported change in body weight exceeding 5% within the 3 months prior to Screening.\n* Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer.\n* Uncontrolled hypertension or unstable cardiovascular disease.\n* History of chronic or acute pancreatitis.\n* Known clinically significant gastric-emptying abnormality or chronic treatment with medications that directly affect gastrointestinal motility.\n* History of suicide attempt.\n* History of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder.\n* Received treatment with semaglutide, tirzepatide, glucagon-like peptide-1 receptor (GLP-1R) agonist, GLP-1\u002Fglucose-dependent insulinotropic polypeptide (GIP), or glucagon receptor agonist within 3 months prior to Screening.\n\nNote: Additional inclusion\u002Fexclusion criteria may apply, per protocol.",{"count":109,"type":22},1200,[63],"The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.",[30],[30,33,34,69,36,114,37,38],"Semaglutide","2026-08-28",{"date":117,"type":43},"2026-09-01",{"date":119,"type":43},"2025-12-30",{"date":121,"type":22},"2028-04",{"name":49,"class":50},59,""]